Waisman Biomanufacturing partners with Heat Biologics to manufacture COVID-19 vaccine

The vaccine will target those most vulnerable to COVID-19 — namely, the elderly and those with health conditions that weaken their immune system. Phase 1 trials could begin in early 2021 and UW–Madison may be a trial site.

Read the full article at: https://news.wisc.edu/72318-2/